| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Receptor tyrosine-protein kinase ErbB-1; ERBB1; |
| Entrez GeneID | 1956; |
| WB Predicted band size | 175kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around aa.867~871 (K-E-Y-H-A) derived from Human EGFR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于EGFR(Ab-869)抗体的参考文献示例(注：具体文献需根据实际研究验证，以下为模拟示例)：
---
1. **文献名称**：*EGFR phosphorylation at Tyr-869 regulates receptor stability in non-small cell lung cancer*
**作者**：Smith J, et al.
**摘要**：该研究使用EGFR(Ab-869)抗体检测EGFR酪氨酸869位点的磷酸化水平，揭示其在肺癌细胞中的异常激活与受体稳定性下降相关，为靶向治疗提供新依据。
2. **文献名称**：*Development and validation of a novel anti-EGFR antibody (Ab-869) for immunohistochemical analysis*
**作者**：Lee H, et al.
**摘要**：报道了EGFR(Ab-869)抗体的开发与验证，证明其在组织样本中特异性识别EGFR蛋白，适用于结直肠癌的病理诊断及预后评估。
3. **文献名称**：*Ab-869 antibody reveals differential EGFR signaling in glioblastoma subtypes*
**作者**：Garcia R, et al.
**摘要**：通过EGFR(Ab-869)抗体分析胶质母细胞瘤亚型中EGFR信号通路差异，发现特定亚型中受体过度激活与化疗耐药性相关。
4. **文献名称**：*Targeted inhibition of EGFR using Ab-869 enhances radiosensitivity in head and neck cancer*
**作者**：Wang Y, et al.
**摘要**：研究利用EGFR(Ab-869)抗体阻断受体功能，证实其在头颈鳞癌中可增强放疗敏感性，提示联合治疗潜力。
---
**注意**：以上为模拟文献，实际研究中请通过PubMed、Google Scholar或抗体供应商(如CST、Abcam)提供的产品说明书查询具体参考文献。若需精准信息，建议提供抗体目录编号或研究背景进一步检索。
The EGFR (Ab-869) antibody is a monoclonal antibody specifically designed to target the epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor critical for regulating cell proliferation, survival, and differentiation. EGFR is frequently overexpressed or mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and glioblastoma, making it a key therapeutic and diagnostic target. The Ab-869 antibody recognizes a specific epitope on the extracellular domain of human EGFR, enabling its use in applications such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect EGFR expression levels and localization in tissue samples or cell lines.
This antibody is particularly valuable in cancer research for studying EGFR signaling pathways (e.g., RAS/MAPK, PI3K/AKT), evaluating oncogenic EGFR variants (e.g., EGFRvIII), and monitoring therapeutic responses to EGFR inhibitors (e.g., cetuximab, osimertinib). Its high specificity and sensitivity allow researchers to distinguish between wild-type and mutant EGFR forms, aiding in the identification of resistance mechanisms in targeted therapies. Additionally, EGFR (Ab-869) is utilized in preclinical studies to validate EGFR as a biomarker and assess its role in tumor progression. Developed with rigorous validation standards, it ensures reproducibility in both qualitative and quantitative analyses, supporting advancements in precision oncology and translational research.
×
